Navigation Links
PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results
Date:1/31/2011

BOSTON, Jan. 31, 2011 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the second quarter ended December 31, 2010.

For the three months ended December 31, 2010, PAREXEL’s consolidated service revenue increased by 6.9% to $304.4 million, compared with $284.7 million in the prior year period.  Excluding the negative impact from foreign exchange movements of $4.8 million, revenue increased 8.6%.  As reported under Generally Accepted Accounting Principles (GAAP), the Company generated operating income of $28.2 million, or 9.3% of consolidated service revenue, in the second quarter of Fiscal Year 2011, versus GAAP operating income of $18.7 million, or 6.6% of consolidated service revenue, in the comparable quarter of the prior year.  The financial results of the December quarter in the current and prior periods each included special items, as detailed in the financial charts within this press release.  Excluding these items in the current period, operating income totaled $27.6 million, or 9.1% of consolidated service revenue.  Excluding special items in the prior year period, operating income totaled $26.9 million, or 9.5% of consolidated service revenue.  On this adjusted basis, operating income in the current quarter grew 2.7% year-over-year.  GAAP net income for the current quarter totaled $16.8 million, or $0.28 per diluted share, compared with GAAP net income of $3.5 million, or $0.06 per diluted share, for the quarter ended December 31, 2009.  Adjusted net income in the current period (excluding special items) was $17.2 million, or $0.29 per diluted share.  Adjusted net income in the prior year quarter (excluding special items) was $15.1 million, or $0.26 per diluted share. Using adjusted numbers, net income in the current quarter grew 13.9%, and earnings per diluted share grew 11.5%.

On a segment basis, consolidated service revenue for the second quarter of Fiscal Year 2011 was $231.4 million in Clinical Research Services (CRS), $32.0 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $41.0 million in Perceptive Informatics, Inc.

The Company’s low current quarter tax rate benefited from a favorable mix of pre-tax profitability, the extension of certain U.S. tax law provisions, and the ongoing benefit of the Company’s approach to transfer pricing.  At the same time, the Company experienced higher than anticipated foreign exchange losses on the Other Expense line, in part due to a short-term disruption to cash flows caused by implementation of the Company’s new billing system.  The Company substantially increased billing during the December quarter, reducing days sales outstanding sequentially to 69 days, while increasing deferred revenue, and decreasing unbilled receivables.

For the six months ended December 31, 2010, consolidated service revenue was $600.2 million versus $544.5 million in the prior year period, an increase of 10.2%.  GAAP operating income for the current six-month period was $58.2 million, or 9.7% of service revenue, compared with GAAP operating income of $37.2 million, or 6.8% of service revenue in the prior year period.  GAAP net income for the six months ended December 31, 2010 was $34.6 million, or $0.58 per diluted share, compared with GAAP net income of $15.9 million, or $0.27 per diluted share, in the prior year period.  Excluding the impact of certain items as detailed in the attached financial charts in both six month periods, operating income was $57.2 million or 9.5% of consolidated service revenue for the six months ended on December 31, 2010, compared with $45.4 million or 8.3% of consolidated service revenue for the six months ended on December 31, 2009.  On an adjusted basis, net income for the six months ended December 31, 2010 was $34.7 million, or $0.58 per diluted share, compared with $27.6 million or $0.47 per diluted share in the comparable prior year six month period.

Backlog at the end of December was approximately $3.0 billion, an increase of 30.9% year-over-year.  Backlog included gross new business wins in the quarter of $496.0 million, cancellations of $100.4 million (3.4% of beginning backlog), and a positive impact from foreign exchange rates of $3.7 million. The net book-to-bill ratio was 1.30 in the quarter.

Mr. Josef H. von Rickenbach, PAREXEL’s Chairman and Chief Executive Officer stated, “During the second quarter, PAREXEL delivered year-over-year revenue growth in all three business segments, and earnings per share that were in line with our expectations.  New business wins and moderate cancellations culminated in record backlog of over $3 billion.  We also experienced a notable increase in proposals from small and emerging biopharma clients during the quarter.”  

“PAREXEL’s global capabilities, expertise, and technology continue to enable us to win healthy new business awards.  At the same time, it has become apparent that the backlog conversion rates inherent in global, complex, clinical development awards generated by strategic partnerships are different from traditional awards.  Our improved understanding of new business dynamics from these partnerships has been reflected in our current forward-looking guidance.”

“As we enter Calendar Year 2011, we are confident in our strategy and that PAREXEL is positioned as a leader in a changing marketplace.  I believe that we have the foundation in place to achieve long-term revenue and earnings growth, and that we will continue to create and deliver value to clients and shareholders.”

The Company issued forward-looking guidance for the third quarter of Fiscal Year 2011 (ending March 31, 2011), for Fiscal Year 2011 and for Calendar Year 2011 using recent exchange rates.  For the third quarter, the Company anticipates reporting consolidated service revenue in the range of $307 to $312 million, and diluted earnings per share in the range of $0.29 to $0.31.  For Fiscal Year 2011, consolidated service revenue is expected to be in the range of $1.22 to $1.24 billion (previously issued revenue guidance was $1.25 to $1.27 billion).  GAAP earnings per diluted share for Fiscal Year 2011 are projected to be in the range of $1.17 and $1.23 (previously issued GAAP earnings per diluted share guidance was $1.23 to $1.31), and adjusted earnings per diluted share (excluding the special items recorded in Q2 FY2011) are projected to be in the range of $1.18 and $1.24.  For Calendar Year 2011, consolidated service revenue is expected to be in the range of $1.260 to $1.295 billion, and GAAP earnings per diluted share are expected to be in the range of $1.21 to $1.31.

Certain trended financial information may be found in the Investor Relations section of the Company’s website under the “Additional Financials” section.  

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures.  The Company believes that presenting the non-GAAP financial measures contained in this press release assists investors and others in gaining a better understanding of its core operating results and future prospects, especially when comparing such results to previous periods or forecasted guidance, because such measures exclude items that are outside of the Company’s normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.  Management uses non-GAAP financial measures, in addition to the measures prepared in accordance with GAAP, as the basis for measuring the Company’s core operating performance and comparing such performance to that of prior periods and to the performance of its competitors for the same reasons stated above.  Such measures are also used by management in its financial and operating decision-making.  Non-GAAP financial measures are not meant to be considered superior to or a substitute for the Company’s results of operations prepared in accordance with GAAP.  

A conference call to discuss PAREXEL’s second quarter earnings, business, and financial outlook will begin at 10:00 a.m. ET on Tuesday, February 1, 2011 and will be broadcast live over the internet via webcast.  The webcast may be accessed in the “Upcoming Events” portion of the main page of the Investor Relations section of the Company’s website at www.parexel.com.  Users should follow the instructions provided to assure that the necessary audio applications are downloaded and installed.  A replay of this webcast will be archived on the website approximately two hours after the call and will continue to be accessible for approximately one year following the live event.  To participate via telephone, dial +1 706-758-4950 and ask to join the PAREXEL quarterly conference call.

About PAREXEL International PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,380 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.  Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 as filed with the SEC on November 9, 2010, which “Risk Factors” discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.CONTACTS:

James Winschel, Senior Vice President and Chief Financial OfficerJill Baker, Corporate Vice President, Investor Relations+1-781-434-4118PAREXEL International Corporation Consolidated Condensed Statement of OperationsUnauditedThree Months EndedThree Months Ended(in thousands, except per share data)December 31, 2010December 31, 2009As ReportedAdjustmentsNon-GAAPAs ReportedAdjustmentsNon-GAAPService revenue$
304,359$  304,359$
284,731$  284,731Reimbursement revenue59,69159,69153,24953,249  Total revenue364,050-364,050337,980337,980Costs and expenses:Direct costs196,475196,475181,276

(a)181,276Reimbursable out-of-pocket expenses59,69159,69153,24953,249Selling, general and administrative 64,19664,19661,459

(a)61,459Depreciation13,60513,60513,151(514)

(b)

12,637Amortization2,4512,4512,4472,447Other benefit --(1,144)1,144

(c)

-Restructuring (benefit) charge(572)572-8,831(8,831)

(d)

-  Total costs and expenses335,846572336,418319,269(8,201)311,068Income from operations28,204(572)27,63218,7118,20126,912Other expense(8,473)1,166

(e)

(7,307)(9,944)6,142

(e)

(3,802)Income before income taxes19,73159420,3258,76714,34323,110Provision for income taxes2,899199

(f)

3,0985,3172,667

(f)

7,984Effective tax rate14.7%15.2%60.6%34.5%Net income$
,832$
395$
7,227$
3,450$
,676$
5,126Earnings per common share:  Basic$
.29$
.29$
.06$
.26  Diluted$
.28$
.29$
.06$
.26Shares used in computing earnings per common share:  Basic58,51658,51657,93357,933  Diluted59,68659,68658,07358,073(a) Prior year numbers have been reclassified to conform with the current year presentation.(b) Accelerated depreciation on abandoned facilities associated with the Q2 FY10 Restructuring Plan.(c) Release of certain reserves associated with a Q2 FY09 charge related to a client contract default.(d) Restructuring charges of $5.2 million related to facilities costs and $3.6 million related to compensation costs.(e) Impairment charges on an asset (FY11) and an investment (FY10).(f) Tax expense related to items above.Balance Sheet InformationPreliminaryDecember 31, June 30,Dec. 31,201020102009Billed accounts receivable, net

$
311,377$
229,932$
250,378Unbilled accounts receivable, net

285,977248,994248,778Deferred revenue

(285,576)(261,080)(287,930)Net receivables

$
311,778$
217,846$
211,226Cash and marketable securities

$
87,552$
7,413$
8,847Working capital

$
217,170$
58,624$
98,461Total assets

$
,356,032$   1,220,710$
,246,994Short-term borrowings

$
,019$
32,082$
32,077Long-term debt

$
72,230$
83,707$
220,330Stockholders' equity

$
516,714$
439,555$
441,229PAREXEL International Corporation Consolidated Condensed Statement of OperationsUnauditedSix Months EndedSix Months Ended(in thousands, except per share data)December 31, 2010December 31, 2009As ReportedAdjustmentsNon-GAAPAs ReportedAdjustmentsNon-GAAPService revenue$
,179$  600,179$
544,494$  544,494Reimbursement revenue106,128106,128101,024101,024  Total revenue706,307-706,307645,518645,518Costs and expenses:Direct costs383,457383,457352,264

(a)352,264Reimbursable out-of-pocket expenses106,128106,128101,024101,024Selling, general and administrative 127,716127,716117,653

(a)117,653Depreciation26,85626,85624,720(514)

(b)

24,206Amortization4,9084,9084,9834,983 Other benefit --(1,144)1,144

(c)

-Restructuring (benefit) charge(962)962-8,831(8,831)

(d)

-  Total costs and expenses648,103962649,065608,331(8,201)600,130Income from operations58,204(962)57,24237,1878,20145,388Other expense(15,788)1,166

(e)

(14,622)(10,724)6,142

(e)

(4,582)Income before income taxes42,41620442,62026,46314,34340,806Provision for income taxes7,79389

(f)

7,88210,5722,667

(f)

13,239Effective tax rate18.4%18.5%40.0%32.4%Net income$
34,623$
5$
34,738$
5,891$
,676$
27,567Earnings per common share:  Basic$
.59$
.59$
.27$
.48  Diluted$
.58$
.58$
.27$
.47Shares used in computing earnings per common share:  Basic58,48358,48357,87457,874  Diluted59,67359,67358,10458,104(a) Prior year numbers have been reclassified to conform with the current year presentation.(b) Accelerated depreciation on abandoned facilities associated with the Q2 FY10 Restructuring Plan.(c) Release of certain reserves associated with a Q2 FY09 charge related to a client contract default.(d) Restructuring charges of $5.2 million related to facilities costs and $3.6 million related to compensation costs.(e) Impairment charges on an asset (FY11) and an investment (FY10).(f) Tax expense related to items above.PAREXEL International CorporationSegment InformationUnauditedThree Months EndedThree Months Ended(in thousands)December 31, 2010December 31, 2009
(a)Clinical Research Services (CRS)Service revenue $
231,364$
221,570% of total service revenue76.0%77.8%Gross profit$
76,856$
79,813Gross margin % of service revenue33.2%36.0%PAREXEL Consulting & Medical Communications  Services (PCMS)Service revenue$
32,013$
29,731% of total service revenue10.5%10.4%Gross profit$
2,864$
,546Gross margin % of service revenue40.2%35.5%Perceptive Informatics, Inc. (PII)Service revenue$
40,982$
33,430% of total service revenue13.5%11.8%Gross profit$
8,164$
3,096Gross margin % of service revenue44.3%39.2%Total service revenue$
304,359$
284,731Total gross profit$
7,884$
3,455Gross margin % of service revenue35.4%36.3%Revenue by GeographyThe Americas$
27,194$
8,913Europe, Middle East & Africa136,201142,459Asia/Pacific40,96433,359Total service revenue$
304,359$
284,731Quarterly Supplemental Financial DataTotal revenue$
364,050$
337,980Investigator fees50,00350,672Gross revenue$
414,053$
388,652Days sales outstanding6950Capital expenditures16,02314,454(a) Prior year numbers have been reclassified to conform with the current year presentation.PAREXEL International CorporationSegment InformationUnauditedSix Months EndedSix Months Ended(in thousands)December 31, 2010December 31, 2009
(a)Clinical Research Services (CRS)Service revenue $
463,003$
423,894% of total service revenue77.1%77.9%Gross profit$
,174$
49,040Gross margin % of service revenue34.6%35.2%PAREXEL Consulting & Medical Communications  Services (PCMS)Service revenue$
,348$
58,552% of total service revenue10.1%10.8%Gross profit$
23,977$
20,763Gross margin % of service revenue39.7%35.5%Perceptive Informatics, Inc. (PII)Service revenue$
76,828$
2,048% of total service revenue12.8%11.3%Gross profit$
32,571$
22,427Gross margin % of service revenue42.4%36.1%Total service revenue$
,179$
544,494Total gross profit$
216,722$
92,230Gross margin % of service revenue36.1%35.3%Revenue by GeographyThe Americas$
260,085$
210,514Europe, Middle East & Africa261,730271,999Asia/Pacific78,36461,981Total service revenue$
,179$
544,494(a) Prior year numbers have been reclassified to conform with the current year presentation.
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call
2. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
3. PAREXEL Announces Date of First Quarter Fiscal Year 2011 Earnings Release and Conference Call
4. PAREXEL Issues Updated Financial And Operational Information
5. PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era
6. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
7. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
8. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
9. PAREXEL International to Present at the Wachovia Equity Conference
10. PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting
11. PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... SHELTON, Conn. , Feb. 8, 2016  NanoViricides, Inc. (NYSE ... that its CEO, Eugene Seymour , MD, MPH, will present ... 5:30PM at the Waldorf-Astoria Hotel in New York City ... presentation will be in the Windsor Room at 5:30PM EST. Registered ... New York City . --> ...
(Date:2/6/2016)... VA (PRWEB) , ... February 06, 2016 , ... The ... session, cost-free, for middle and high school teachers on Wednesday February 10, 2016. ... held at the Smithsonian-Mason School of Conservation, located at 1500 Remount Road in Front ...
(Date:2/5/2016)... On Thursday, February 11, 2-1-1 San ... health and disaster services, and the Community Information ... care coordination and service delivery for the community to ... to better connect service providers to the information they ... Diego has handled more than 2.5 million ...
(Date:2/4/2016)... , February 4, 2016 - New FDA action date ... New FDA action date of July 22, ... July 22, 2016   - Lifitegrast ... the past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in the ...
Breaking Biology Technology:
(Date:1/25/2016)...  Glencoe Software, the world-leading supplier of image data ... provide the data management solution OMERO Plus for the ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of ... states such as health and disease, the presence or ...
(Date:1/21/2016)... --> ... report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, NLP, ... Voice Recognition and Others), Services, Application Areas, End ... published by MarketsandMarkets, the global Emotion Detection and ... Billion by 2020, at a CAGR of 31.9%, ...
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
Breaking Biology News(10 mins):